SIL KASALLIGI: ZAMONAVIY TASHXIS USULLARI VA DAVOLASH PROTOKOLLARI
Published
May 20, 2026
Issue
Vol. 1 No. 1 (2026): Journal of Global Scientific Innovations
Pages
37-42
Open Access
Abstract
Sil kasalligi (tuberkulyoz) hozirgi kunda ham global sog'liqni saqlash tizimining dolzarb muammolaridan biri bo'lib qolmoqda. Maqolada Mycobacterium tuberculosis qo'zg'atuvchisining biologik xususiyatlari, kasallikning patogenetik mexanizmlari, klinik ko'rinishlarining xilma-xilligi, zamonaviy tashxis algoritmlari hamda Jahon sog'liqni saqlash tashkiloti (JSST) tavsiyalariga asoslangan davolash protokollari klinik-epidemiologik nuqtai nazardan yoritilgan. Multidrug-resistant tuberculosis (MDR-TB) va extensively drug-resistant tuberculosis (XDR-TB) muammosining o'sib borishi fonida yangi avlod diagnostik vositalar va davolash sxemalarini amaliyotga joriy etishning zarurati alohida ta'kidlanadi.
Keywords:
sil kasalligi, tuberkulyoz, Mycobacterium tuberculosis, MDR-TB, GeneXpert, DOTS strategiyasi, ftiziatriya, davolash protokoli, profilaktika, BCG emlash.
Maqolani onlayn o'qish
Maqola matni yuklanmoqda, iltimos kuting...
References
- [1] World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023. 278 p.
- [2] World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Geneva: WHO; 2022. 196 p.
- [3] O'zbekiston Respublikasi Sog'liqni saqlash vazirligi. Tuberkulyozga qarshi kurash bo'yicha milliy dastur, 2020–2025. Toshkent; 2020.
- [4] Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.
- [5] Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol. 2012;12(8):581–591.
- [6] Raviglione M, Sulis G. Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination. Infect Dis Rep. 2016;8(2):6570.
- [7] Lawn SD, Nicol MP. Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011;6(9):1067–1082.
- [8] Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state. Chest. 2012;142(1):63–75.
- [9] Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893–902.
- [10] World Health Organization. WHO guidelines on tuberculosis infection prevention and control, 2019 update. Geneva: WHO; 2019. 74 p.